Heatwave Mounjaro warning issued for millions as temperatures soar
As the UK braces itself for a heatwave over the next few weeks, with temperatures expected to reach 32C, patients using weight loss medication such as Mounjaro have been issued essential advice by pharmacists.
It's estimated that around 1.5 million Brits are now taking weight-loss drugs, with numbers increasing each week.
The last year has seen a huge increase in the number of people taking GLP-1 receptor agonists, some prescribed by the NHS and others by private doctors, with common injectibles including semaglutide (Wegovy and Ozempic), tirzepatide (Mounjaro) and liraglutide (Saxenda).
As the temperatures rise, experts are stressing that users must store weight loss injections in a refrigerator (2-8°C or 36-46°F), especially after starting the course.
Review your ICB's local policy about treating patients with tirzepatide (Mounjaro) for weight management in a primary care setting and visit: https://t.co/03msJjjTU9 pic.twitter.com/tHs6lyJHc4
— We are Primary Care (@PrimaryCareNHS) June 12, 2025
'Weight loss injections can be adversely affected by hot weather, particularly regarding storage and stability," says James O'Loan, obesity specialist and weight loss injection expert at pharmacists Chemist4U.
"Understanding the storage instructions when using any prescribed medication is vital to keep it in optimal condition.
"Although weight loss injections can be stored at room temperature for up to 30 days (some injections are 42 days, so always check with your prescriber or refer to the patient information leaflet), this is only provided the temperature does not exceed 30°C. During hot weather, and to be on the safe side, it is always best to keep your weight loss injections refrigerated if you're able."
The advice for the UK heatwave is also also worth noting for those heading on holiday or travelling during the warmer weather.
However, if you're flying, remember to pack your injections in your carry-on since the baggage hold on a plane can plummet to below-freezing temperatures.
Finding the right temperature for your pen is important: not too hot or too cold. If you inject after incorrectly storing your pen, it might not be safe for use.
"There are a few important things to consider when checking if your weight loss pen is safe to use," says James.
"Inspect the pen to ensure it is not damaged and the medicine inside is clear, with no particles or cloudiness. The liquid should be colourless or slightly yellow. If you have left your pen unrefrigerated during hot weather and are unsure whether it is still safe to use, always consult your prescriber before injecting.
"Staying hydrated whilst taking weight loss injections is key. Weight loss injections can cause side effects such as nausea, constipation, diarrhoea and dizziness, which, without sufficient fluids, can lead to dehydration.
"We recommend drinking plenty of water throughout the day, even when you're not thirsty. If experiencing diarrhoea or vomiting, try using electrolyte drinks, rehydrate quickly and apply sunscreen whenever you are outdoors. This will help those who suffer from heightened sensitivity to UV rays.'
Yes. Travel insurance providers are warning that the growing number of Brits turning to these breakthrough drugs for weight management could lose their cover and face huge medical bills abroad if they don't declare their usage when arranging travel insurance.
Many don't want to admit they are taking the weight-loss drugs, or think that if they buy it privately, it doesn't need to be declared.
Niraj Mamtora, director at Forum Insurance, says: 'Weight-loss medications like Ozempic are transforming lives across the UK, but too many travellers don't realise the insurance implications. If you're using these drugs, you must declare both the medication and the condition it's prescribed for.
'Failure to do so is not a minor oversight - it's a serious breach of your travel insurance contract. If you need medical help overseas and haven't declared your medication, your claim can be refused and your policy cancelled. The financial consequences can be severe.'
Recommended reading:
When will Mounjaro be rolled out on the NHS?
Mounjaro and Ozempic warning for anyone planning a holiday this summer
Warning as Mounjaro and Ozempic sold without prescription
'Non-disclosure is a gamble that's simply not worth taking," says Niraj.
"If you don't declare your medication or the underlying condition, your insurer is within their rights to refuse any claim, even if it seems unrelated.
'Many travellers only discover too late that their travel insurance claims are rejected, leaving them without support and facing potentially huge bills.
"With the average medical claim abroad now exceeding £1,700, and costs rising significantly with age, being properly covered is more important than ever.'
Insurance claims related to undeclared conditions or medications can be refused, even if the issue seems unrelated.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
40 minutes ago
- CNN
Dozens in northeast England report symptoms of potentially deadly botulism after getting Botox
Health officials in the UK are investigating reports of dozens of people suffering from a potentially life-threatening condition following Botox procedures in northeastern England, as well as allegations of the illegal sale of Botox-like products. The local trust of the UK's National Health Service (NHS) in the county of Durham put out an alert on June 13 about several people seeking medical attention after having adverse reactions to cosmetic procedures involving Botox. Since the incident first came to light last week, 28 individuals have reported symptoms of botulism after receiving cosmetic procedures, the UK Health and Security Agency (UKHSA) told CNN in a statement Friday. Botulism is a life-threatening condition caused by toxins made by Clostridium botulinum bacteria that attack the nervous system and cause paralysis. 'These toxins (but not the bacteria) are the active ingredient in Botox and similar products,' Dr. Joanne Darke, a consultant in health protection at the UKHSA, said in the statement, adding that it is 'important to go to a licensed practitioner.' Iatrogenic botulism is a type of botulism that occurs when too much of the cosmetic form, Botox, is injected into a muscle. Botox is a leading cosmetic treatment for wrinkles, as well as for medical conditions such as migraines and excessive sweating. The UKHSA said the reactions reported have included symptoms of severe drooping of the upper eyelids, double vision, difficulty swallowing, slurred speech and lethargy. Other symptoms of botulism can include facial muscle weakness. Botulism requires immediate medical attention and is fatal in 5-10% of cases, according to the NHS website. While most people make a full recovery with treatment, which typically involves getting injections with antitoxins, without quick care, paralysis can spread to muscles used to control breathing. While investigations into the cause of the cases are ongoing, the UKHSA said that 'evidence so far does not suggest that the product used has been contaminated. Symptoms are being reported a few days up to four weeks after injection.' 'The practitioners associated with most of the reported cases are no longer carrying out these procedures,' said Dr. Simon Howard, a consultant in health protection at the UKHSA, in the statement. 'However, that does not mean that we may not see more cases as symptoms can take up to four weeks to develop although we are now seeing the number of cases coming forward decreasing which is encouraging news,' he continued. Howard advised people to ensure they take precautions when seeking aesthetic procedures and advised anyone with symptoms to seek medical attention. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) told CNN Friday that it is investigating 'allegations surrounding the illegal sale and supply of Botox-type products in the North-East, and want to reassure the public that we take such claims very seriously.' The agency encouraged people in the UK who believe they have had side effects from medicine or received falsified stock to report it to its Yellow Card program. 'Our Criminal Enforcement Unit works hard to identify those involved in the illegal trade in medicines and takes robust enforcement action where necessary. This can include criminal prosecution,' Dr. Alison Cave, chief safety officer at MHRA, said in the statement. 'Botulinum toxin (Botox) is a prescription-only medicine and should only be available in the UK under the supervision of a doctor or other qualified healthcare professional,' she continued. In the United States, a growing cluster of botulism cases linked to cosmetic injections was reported in Massachusetts earlier this month. The state's Department of Health said it was investigating 10 cases of suspected iatrogenic botulism all associated with Botox procedures performed at one spa, Rodrigo Beauty.
Medscape
2 hours ago
- Medscape
ICU Skin Decolonisation May Raise Resistant Infections
Universal skin decolonisation of patients admitted to intensive care units (ICU) may not improve infection control. New research led by the University of Aberdeen indicated that it might increase meticillin-resistant Staphylococcus epidermidis (MRSE) bloodstream infections in vulnerable patients. Hospital-associated infections cause significant morbidity and mortality, with critically ill patients in ICUs at particularly high risk. Surveillance figures from English ICUs show an ICU-associated bloodstream infection rate of 3.5 per 1000 bed-days for stays of two nights or more in the year to March 2024. Over 25% of patients with these infections die within 30 days. Reasons for the increased infection rate in ICUs include high antibiotic use leading to significant skin flora colonisation by resistant bacteria. Invasive procedures including indwelling catheters and the insertion of intravascular devices are independently associated with meticillin-resistant Staphylococcus aureus (MRSA) colonisation and infection. Need for a New Infection Control Approach Decolonisation protocols were introduced in the 1990s to curb rising nosocomial MRSA infections due to MRSA. Nationwide infection control programmes since the mid-2000s led to sharp declines in MRSA rates in NHS hospitals over the next decade. One UK-wide study in ICU patients between 2007 and 2016 showed a 78% decrease in bloodstream infections overall and a 97% reduction in MRSA bloodstream infections. However, data from the National Institute for Health and Care Research show this decline plateaued after 2012. Rates have subsequently been largely static, suggesting the need for a new approach. Routine ICU decolonisation typically involves chlorhexidine skin disinfection combined with nasal mupirocin. The Aberdeen team noted conflicting evidence on chlorhexidine's effectiveness. They also raised concerns that biocide skin and mucous membrane decolonisation might lead to reduced susceptibility to chlorhexidine and selection for multidrug-resistant pathogens. Study Compares Universal and Targeted Decolonisation The researchers compared universal versus targeted skin and nasal decolonisation in ICU patients at two Scottish hospitals in adjacent health boards with different protocols. The study included patients aged 16 years and over admitted between 1 July 2009 and 28 Feb 2022. One hospital switched from universal decolonisation of all admissions to targeting only MRSA carriers from 1 February 2019. The other hospital used targeted decolonisation throughout. The researchers analysed rates of S. epidermidis bloodstream infections and tested MRSE and chlorhexidine susceptibility. Results Show Benefits in Reducing Resistant Infections The results, published in The Lancet Microbe , showed that S epidermidis was identified in 334 (45%) of 735 bloodstream infections in the hospital that de-escalated decolonisation. Of these, 197 occurred before de-escalation. Overall, bloodstream infection rates did not increase after de-escalation. However, MRSE infections declined significantly after the switch – from 10.4 to 4.3 cases per 1000 occupied bed days. The probability of MRSE among infections fell from 89.2% to 56.7%. By contrast, the control hospital reported 167 (60%) S. epidermidis bloodstream infections among 278 total, with no significant changes in infection rates or MRSE incidence. Genetic analyses revealed de-escalation was linked to fewer bloodstream infections caused by multidrug-resistant S. epidermidis strains. There was reduced carriage of mobile genetic elements and genes related to multidrug resistance and biofilm production. Balancing Benefits and Risks "In ICU settings with low MRSA incidence, the benefits of universal decolonisation should be balanced against the risks of selecting MRSE sequence types adapted for invasive and device-associated infection," the researchers concluded. Professor Karolin Hijazi, chair in oral and maxillofacial medicine at the University of Aberdeen and study lead, commented in a press release: "This research essentially demonstrates that the excess use of disinfectants in universal decolonisation offered no advantage in terms of control of serious blood infections in a low MRSA ICU setting, but instead caused the unintended rise of MRSE bloodstream infections." Implications for Infection Control Policy The authors recommended that hospitals consider the "unintended harms of universal decolonisation", especially given the global rise of antimicrobial resistance. Hijazi added that such practices increase resistance risks and costs without added benefit in low-MRSA settings. The findings should inform standardised national guidelines for effective and safe patient decolonisation, in line with the government's 5-year action plan for antimicrobial resistance, the researchers said. They described the emergence and spread of antimicrobial resistance as a 'silent pandemic' and stressed that reducing unnecessary decolonisation could help contain resistance and reduce costs.
Health Line
2 hours ago
- Health Line
GLP-1 Weight Loss Results Not as Effective in Everyday Life, Study Finds
Researchers report that people taking GLP-1 drugs in daily life don't lose as much weight as those in clinical trials who take the same medications. The researchers add that people using weight loss drugs don't regain weight as quickly as those in clinical trials. One possible reason for the weight loss differential is that people in the 'real world' tend to stop taking these medications sooner than people in clinical trials. People who use commonly prescribed weight loss medications don't lose as much weight as participants in clinical trials, but they also don't regain weight as quickly. That's the conclusion of a new study published on June 10 in the journal Obesity. The study authors reported that the weight loss differential was mainly due to the fact that people tend to stop using GLP-1 drugs sooner than clinical trial participants. They also tend to use lower doses of these medications. The researchers also reported that A1C blood level reductions were similar for both groups of people. The researchers noted that they will initiate further research into what other measures, such as lifestyle changes or bariatric surgery, people may have adopted after discontinuing weight loss medications such as Wegovy and Zepbound. The researchers also want to look into why people stopped using weight loss drugs before their program regimen ended. 'Our findings indicate that treatment discontinuation and use of lower maintenance dosages might reduce the likelihood of achieving clinically meaningful weight reduction in patients who initiate obesity pharmacotherapy with semaglutide or tirzepatide,' the study authors wrote. 'Our findings could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight loss,' they added. 'Real world' use of weight loss medications For their study, researchers looked at the health records of 7,881 adults with obesity or weight management issues who did not have type 2 diabetes. Those people were seen between 2021 and 2023 at the Cleveland Clinic's facilities in Ohio and Florida. Their average age was about 51 years. Nearly 80% of the subjects were white. Of those participants, 6,109 were prescribed a weight loss medication such as Wegovy with the active ingredient semaglutide. The other 1,772 were prescribed a weight loss drug, such as Zepbound, with the active ingredient tirzepatide. About 80% of those subjects were given low doses of their weekly injectable weight loss medications. Researchers reported significant differences between people using weight loss medications in phase 3 clinical trials and those taking the drugs in the 'real world.' For starters, about half of those taking either medication in daily life stopped within the first 12 months. About 51% of those using a tirzepatide drug discontinued its use in that same time period. That compares with only 17% of semaglutide users and between 14% and 16% of tirzepatide users in clinical trials who quit during the first year. In addition, the average weight reduction for semaglutide participants in daily life was nearly 8% after one year while it was 12% for people taking tirzepatide. By comparison, the average weight loss in clinical trials was nearly 15% for semaglutide subjects as well as 15% for people on low dose tirzepatide and 20% for those on a higher dose of that medication. In general, weight loss was greater in people who took weight loss medications for a longer period of time. In addition, about 54% of people who had prediabetes at the start of their treatment plan improved to healthier A1C levels after one year. Around 3% of those studied progressed to type 2 diabetes after 12 months. Weight loss is a long-term commitment Mir Ali, MD, a surgeon and bariatric surgeon as well as the medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in California, said the main takeaway from this study is that weight loss is a long-term commitment. Ali wasn't involved in the new study. 'The long-term use of medications is more effective than short-term use,' Ali told Healthline. 'The study confirms that obesity is a chronic condition like diabetes or hypertension.' Sarah Kim, MD, a professor of medicine at the University of California San Francisco, noted that discontinuing medication is common for people being treated for obesity and other conditions. Kim was likewise not involved in the new study. Kim added that adherence to medication schedules as well as diet and exercise programs isn't as easy in real life because people don't have the supervision and support a person gets during a clinical trial. 'Real life is different and results aren't always as spectacular as in clinical trials,' Kim told Healthline. Kim and Ali agreed that another reason people stop taking medications is that these drugs can be expensive, even if insurance is picking up part of the cost. There is also the fact that the side effects from these medications can be severe for some people. Plus, people in real life sometimes just get tired of the obligation of taking a pill or injecting themselves on a regular basis. Ali and Kim also noted that people need to realize that medications are only a tool to help them eat less. To lose weight and keep it off, a person needs to adopt lifestyle habits such as a healthy diet and regular exercise. 'The medications are not a short-term kickstart. They don't burn fat,' said Kim. 'The medications just help with the suppression of hunger.' 'The ultimate goal of the medications is to give people a tool to get them to a healthy weight,' Ali added. What to know about GLP-1 drug for weight loss Glucagon-like peptide-1 receptor agonists (GLP-1s) work by mimicking a hormone in the body that helps regulate blood sugar levels and reduces hunger pangs. One class of the newer GLP-1 medications uses the active ingredient semaglutide. They are sold under different brand names. Ozempic and Rybelsus have been approved to treat type 2 diabetes. Wegovy is approved for use in weight management. Semaglutide drugs are available as both oral tablets and injections. The other newer group uses the active ingredient tirzepatide. Mounjaro is approved to treat type 2 diabetes. Zepbound is approved for use in weight management. These medications are available only as injections. Previous studies have highlighted the effectiveness of these drugs on helping people lose weight. Past research has also indicated that these weight loss drugs can help lower a person's risk of cancer as well as provide benefits to heart health and brain health. Experts say the medications have proven to be effective and their use is likely to increase. 'This is a massive market and it's not going to go away,' Ali said. 'These medications are going to continue to be a big part of weight loss programs.'
